D. Kirkpatrick

发表

Utilization of distillers dried grains with solubles and phytase in sow lactation diets to meet the phosphorus requirement of the sow and reduce fecal phosphorus concentration.

G. Hill, J. Link, M. Rincker, 2008, Journal of animal science.

Molecular pharmacology and antitumor activity of palmarumycin-based inhibitors of thioredoxin reductase

P. Wipf, D. Kirkpatrick, G. Powis, 2006, Molecular Cancer Therapeutics.

Synthesis and evaluation of some alkoxy-, chloro-, and acyloxy-conjugated styryl ketones against P-388 lymphocytic leukemia and an examination of the metabolism and toxicological effects of 1-(m-ethoxymethyloxyphenyl)-1-nonen-3-one in rats.

D. Kirkpatrick, J. Dimmock, N. G. Webb, 1982, Journal of pharmaceutical sciences.

Clinically Evaluated Cancer Drugs Inhibiting Redox Signaling.

D. Kirkpatrick, G. Powis, D. Kirkpatrick, 2017, Antioxidants & redox signaling.

Thioredoxin signaling as a target for cancer therapy.

D. Kirkpatrick, G. Powis, 2007, Current opinion in pharmacology.

Evaluation of nafamostat mesylate safety and inhibition of SARS-CoV-2 replication using a 3-dimensional human airway epithelia model

D. Kirkpatrick, J. Millard, 2020, bioRxiv.

Synthesis and cytotoxic evaluation of some 6-arylidene-2-(alpha-hydroxyamino-alpha-arylmethyl)cyclohexanone oximes and related compounds.

M. Duffy, D. Kirkpatrick, Z. Jia, 1992, Journal of pharmaceutical sciences.

The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation.

D. Kirkpatrick, G. Powis, S. Welsh, 2003, Molecular cancer therapeutics.

Selenium and the thioredoxin redox system: effects on cell growth and death.

D. Kirkpatrick, G. Powis, J. Gasdaska, 1997, Oncology research.

Oxidative inactivation of thioredoxin as a cellular growth factor and protection by a Cys73-->Ser mutation.

D. Kirkpatrick, G. Powis, J. Gasdaska, 1996, Biochemical pharmacology.

Phase I trial of PX-866, a novel phosphoinositide-3-kinase (PI-3K) inhibitor.

A. Jimeno, R. Herbst, R. Kurzrock, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase IB trial of 24-hour intravenous PX-12, a thioredoxin-1 inhibitor, in patients with advanced gastrointestinal cancers

N. Raghunand, D. Kirkpatrick, M. Boice, 2013, Investigational New Drugs.

Modification of antitumor disulfide cytotoxicity by glutathione depletion in murine cells.

D. Kirkpatrick, 1987, Cancer research.

Mechanisms of inhibition of the thioredoxin growth factor system by antitumor 2-imidazolyl disulfides.

M. Kunkel, D. Kirkpatrick, G. Powis, 1998, Biochemical pharmacology.

Kinetic study of the interaction of glutathione with four antitumor disulfides: possible mechanism for cellular glutathione depletion.

D. Kirkpatrick, 1989, Chemico-biological interactions.

The thioredoxin/thioredoxin reductase redox system and control of cell growth.

D. Kirkpatrick, G. Powis, M. Berggren, 1994, Oncology research.

Thioredoxin redox control of cell growth and death and the effects of inhibitors.

D. Kirkpatrick, G. Powis, A. Baker, 1998, Chemico-biological interactions.

A Phase I Pharmacokinetic and Pharmacodynamic Study of PX-12, a Novel Inhibitor of Thioredoxin-1, in Patients with Advanced Solid Tumors

S. Green, D. Kirkpatrick, A. Baker, 2007, Clinical Cancer Research.

Influence of application methods on the degradation of permethrin in laboratory, soil aerobic metabolism studies

D. Shaw, D. Kirkpatrick, M. Skidmore, 1994 .

Enantiomeric impurity analysis using circular dichroism spectroscopy with United States Pharmacopeia liquid chromatographic methods

M. Trehy, D. Kirkpatrick, Margaret Fain, 2018, Journal of Pharmaceutical and Biomedical Analysis.

Determination of the enantiomeric purity of epinephrine by HPLC with circular dichroism detection

M. Trehy, D. Kirkpatrick, Jingyue Yang, 2017, Journal of liquid chromatography & related technologies.

UHPLC assay and impurity methods for diphenhydramine and phenylephrine hydrochloride oral solution.

D. Kirkpatrick, Margaret Fain, Jingyue Yang, 2019, Separation science plus.

The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma.

Chiu-Hsieh Hsu, D. Kirkpatrick, G. Powis, 2006, The Journal of laboratory and clinical medicine.

Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma.

W. Yung, Yiling Lu, D. Kirkpatrick, 2010, Neuro-oncology.

The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non–small cell lung cancer xenografts

P. Wipf, G. Paine-Murrieta, D. Kirkpatrick, 2005, Molecular Cancer Therapeutics.

(o- and p-Nitrobenzyloxycarbonyl)-5-fluorouracil derivatives as potential conjugated bioreductive alkylating agents.

D. Kirkpatrick, A. Sartorelli, T. Lin, 1986, Journal of medicinal chemistry.

Practicalities of Drugging the Phosphatidylinositol-3-Kinase/Akt Cell Survival Signaling Pathway

D. Kirkpatrick, G. Powis, N. Ihle, 2006, Clinical Cancer Research.

Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance.

G. Mills, P. Wipf, P. Dent, 2009, Cancer research.

Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1α

D. Kirkpatrick, G. Powis, S. Welsh, 2008, Molecular Cancer Therapeutics.

Chemosensitivity testing of fresh human leukemia cells using both a dye exclusion assay and a tetrazolium dye (MTT) assay.

D. Kirkpatrick, M. Duke, T. S. Goh, 1990, Leukemia research.

Multi-Drug/Gene NASH Therapy Delivery and Selective Hyperspectral NIR Imaging Using Chirality-Sorted Single-Walled Carbon Nanotubes

D. Kirkpatrick, A. Naumov, M. Hasan, 2019, Cancers.

Cell line-directed screening assay for inhibitors of thioredoxin reductase signaling as potential anti-cancer drugs.

M. Kunkel, D. Kirkpatrick, G. Powis, 1997, Anti-cancer drug design.

Parallel syntheses of disulfide inhibitors of the thioredoxin redox system as potential antitumor agents.

M. Kunkel, D. Kirkpatrick, G. Powis, 1999, Anti-cancer drug design.

Synthesis and evaluation of imidazolyl disulfides for selective cytotoxicity to hypoxic EMT6 tumor cells in vitro

D. Kirkpatrick, T. Chen, Ml Jimale, 1992 .

Nitrobenzyl derivatives as bioreductive alkylating agents: evidence for the reductive formation of a reactive intermediate.

D. Kirkpatrick, A. Sartorelli, K. E. Johnson, 1986, Journal of medicinal chemistry.

Inhibitory effects of cytotoxic disulfides on membrane Na+, K(+)-ATPase.

D. Kirkpatrick, K. King, 1990, Biochemical Pharmacology.

Effect of 4-dimethylaminomethyl-1-(3-hydroxyphenyl)-1-nonen-3-one hydrochloride and related compounds on respiration in rat liver mitochondria.

D. Kirkpatrick, J. Dimmock, N. Hamon, 1982, Journal of pharmaceutical sciences.

Molecular Pharmacology and Antitumor Activity of PHT-427, a Novel Akt/Phosphatidylinositide-Dependent Protein Kinase 1 Pleckstrin Homology Domain Inhibitor

Eugene A. Mash, Lei Du-Cuny, Emmanuelle J. Meuillet, 2010, Molecular Cancer Therapeutics.

Solubility, ionization, and partitioning behavior of unsymmetrical disulfide compounds: alkyl 2-imidazolyl disulfides.

J. Lazo, D. Kirkpatrick, L. Block, 2002, Journal of pharmaceutical sciences.

Carbon Nanotubes: Solution for the Therapeutic Delivery of siRNA?

R. Weisman, D. Kirkpatrick, A. Naumov, 2012, Materials.

Development and validation of assay and impurities methods for acetaminophen and diphenhydramine tablets

D. Kirkpatrick, M. Momot, C. Anthony, 2020 .

Structure-based drug design: combinatorial chemistry and molecular modeling.

D. Kirkpatrick, S. Ulhaq, D L Kirkpatrick, 1999, Combinatorial chemistry & high throughput screening.

Redox active disulfides: the thioredoxin system as a drug target.

M. Kunkel, D. Kirkpatrick, G. Powis, 1997, Oncology research.

Evaluation of the cytotoxicity of some Mannich bases of acetophenone against the EMT6 tumour.

D. Kirkpatrick, J. Dimmock, E. Erciyas, 1990, Die Pharmazie.

Evaluation of the citotoxicity of some Mannich base of acetophenone againt the EMT6 tumour

D. Kirkpatrick, J. Dimmock, E. Erciyas, 1990 .

Modification of the DiSC assay by the incorporation of monoclonal antibody staining.

D. Kirkpatrick, T. S. Goh, L. Chen, 1992, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.

Molecular pharmacology and antitumor activity of palmarumycin-based inhibitors of thioredoxin reductase

P. Wipf, D. Kirkpatrick, G. Powis, 2006, Molecular Cancer Therapeutics.